Executive Director, Head of US Rare Endocrinology and Rare Tumors

AstraZeneca•Boston, MA

1d•$282,046 - $423,070•Hybrid

About The Position

The Executive Director, Head of US Rare Endocrinology and Rare Tumors provides senior medical leadership and full US Medical Affairs strategic ownership for Alexion’s Rare Endocrinology and Rare Tumors portfolio. The role defines and implements portfolio-wide US Medical Affairs strategy across marketed products, pipeline assets, launch readiness, indication expansion, and lifecycle management, aligned with Global Medical Affairs strategy, US business priorities, and patient-centered objectives. The leader advances understanding of the US medical and treatment landscape, sets strategy and tactical plans, represents the therapeutic area in leadership and governance forums, and leads and develops the Medical Affairs team. The role establishes portfolio priorities, resource needs, and budgets; partners with cross-functional teams; and provides leadership for launch readiness, lifecycle management, and evidence generation. It also oversees activity reviews, publication planning, scientific exchange, external expert engagement, medical education and training, compliant content review, and strategic adoption of AI and digital innovation. The position is based on an average expectation of at least three days per week in the office, with flexibility. Annual base pay ranges from $282,046.40 to $423,069.60, with a short-term incentive bonus opportunity and eligibility for an equity-based long-term incentive program. Benefits include a qualified retirement program (401(k)), paid vacation and holidays, paid leaves, and medical, prescription drug, dental, and vision coverage.

Requirements

Advanced scientific or clinical degree, including M.D., PharmD, Ph.D., or equivalent advanced degree.
Minimum of 12 years of biopharmaceutical industry experience, with significant Medical Affairs leadership responsibility.
Minimum of 10 years leading and managing teams, including Medical Affairs organizations.
Demonstrated experience developing and implementing medical strategy across multiple assets, indications, or product lifecycle stages, including marketed and pipeline assets.
Demonstrated ability to influence senior leaders, external experts, and cross-functional partners while advancing medical strategies that improve patient care and outcomes.
Demonstrated ability to use digital, data, and AI-enabled capabilities to improve organizational effectiveness, accelerate decision making, and enhance Medical Affairs impact.

Nice To Haves

Rare disease experience; endocrinology, oncology, rare tumors, or a related therapeutic area is strongly preferred.
Product lifecycle management, launch readiness, and indication expansion experience.
Experience in early- and late-stage clinical development, evidence generation, real-world evidence, and/or investigator-sponsored research.
Experience representing a therapeutic area in senior leadership forums, global governance discussions, major congresses, professional societies, advocacy engagements, or external scientific forums.
Experience leading Medical Affairs strategy for a rare disease portfolio involving small patient populations, complex diagnostic pathways, and specialized centers of excellence.

Responsibilities

Advance understanding of the US Rare Endocrinology and Rare Tumors medical and treatment landscape, including standards of care, patient needs, evidence gaps, expert perspectives, and scientific developments, to inform US Medical Affairs strategies aligned with Global priorities.
Lead strategy and tactical plan design and execution for assigned tumor areas, aligned with Global strategy and US priorities.
Serve as the senior US medical leader for the therapeutic area in US leadership forums, global governance discussions, and cross-functional portfolio planning.
Lead and develop the Medical Affairs team, including Medical Directors, Regional MSL Directors, Medical Science Liaisons, and other therapeutic area team members as applicable.
Define portfolio priorities, resource needs, and budget planning across tumor areas, linking trade-off decisions to patient impact, evidence gaps, launch priorities, and business-critical achievements.
Partner with Commercial, Market Access, HEOR, Regulatory, Clinical Development, Medical Operations, Patient Advocacy, and Global Medical Affairs to align and coordinate planning.
Lead launch readiness, lifecycle management, and evidence generation, including identification of data gaps and prioritization of real-world evidence, investigator-sponsored research, and company-sponsored research opportunities.
Lead monthly and quarterly reviews of US Medical Affairs activities, including field medical performance, medical insights, evidence generation, and tactical plan execution.
Ensure timely, high-quality publication planning and medical communications in support of Global and US Medical Affairs strategy.
Drive scientific exchange strategy, advisory boards, congress engagement, thought leader development, and external expert engagement across relevant rare disease communities.
Collaborate with HEOR and other partners to turn medical insights and evidence gaps into strategic actions supporting improved patient care and outcomes.
Partner with Global Medical Education and internal scientific training teams to localize and develop medical content for field medical scientific exchange and cross-functional education.
Ensure medically accurate, scientifically balanced, compliant review of promotional and non-promotional materials, as appropriate for the role.
Drive strategic adoption of AI and digital innovation within the Rare Endocrinology and Rare Tumors Medical Affairs organization.
Identify training and development needs with key partners and ensure implementation of medical training programs for field medical teams and other team members as appropriate.